Posted On: 10/28/2015 8:56:54 PM
Post# of 30034
Re: All Aboard #21137
Good catch (i.e. "Amarantus Evaluating Strategic Options for Eltoprazine Phase 2b Study" )
Also worth noting in regards to Eltoprazine :
- Eltoprazine ADHD is potentially Phase 3 ready per Oct. 20 presentation
- Eltoprazine Alzheimer's Aggression was pulled off the pipeline road map in the slides (but still on the website). However it is on slide 30 and GC did mention it.
- Company submitted Orphan Drug Designation to US FDA for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia last week
- Osmotica Pharmaceutical Corp (Private) and Adamas Pharmaceuticals (ADMS) have already received ODD for LID
- Very strong safety track record
Also worth noting in regards to Eltoprazine :
- Eltoprazine ADHD is potentially Phase 3 ready per Oct. 20 presentation
- Eltoprazine Alzheimer's Aggression was pulled off the pipeline road map in the slides (but still on the website). However it is on slide 30 and GC did mention it.
- Company submitted Orphan Drug Designation to US FDA for Eltoprazine in the Treatment of Levodopa-Induced Dyskinesia last week
- Osmotica Pharmaceutical Corp (Private) and Adamas Pharmaceuticals (ADMS) have already received ODD for LID
- Very strong safety track record
(0)
(0)Scroll down for more posts ▼
